Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC)

Lung Cancer

Volumn 53, Issue 3, 2006, Pages 347-353

  Raez, Luis E ^a   Santos, Edgardo S ^a   Lopes, Gilberto ^a   Rosado, Manuel F ^a   Negret, Lawrence M ^a   Rocha Lima, Caio ^a   Tolba, Kalhed ^a   Farfan, Nancy ^a   Hamilton Nelson, Kara ^b   Silva, Orlando ^a   Roman, Eloy ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Advanced disease; Chemotherapy; Docetaxel; First line therapy; Non small cell lung cancer; Oxaliplatin

Indexed keywords

DEXAMETHASONE; DOCETAXEL; METOCLOPRAMIDE; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 RECEPTOR;

ADRENAL METASTASIS; ADULT; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; LEUKOCYTOSIS; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOCYTOSIS; TONGUE SWELLING; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TAXOIDS; TREATMENT OUTCOME;

EID: 33746886649     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.05.023     Document Type: Article

References (32)

1. SEER Cancer Statistics Review 1975-2000. National Cancer Institute (Accessed November 2, 2005 at http://www.seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005).
2. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311 7010 (1995) 899-909
3. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 2 (2004) 330-353
4. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 21 (2002) 4285-4291
5. Rosell R., Gatzemeier U., Betticher D.C., Keppler U., Macha H.N., Pirker R., et al. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13 10 (2002) 1539-1549
6. Cvitkovic E. Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer 77 Suppl. 4 (1998) 8-11
7. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 1 (2004) 23-30
8. Monnet I., Brienza S., Hugret F., Voisin S., Gastiaburu J., Saltiel J.C., et al. Phase II study of oxaliplatin in poor-prognosis non-small-cell lung cancer (NSCLC). Eur J Cancer 34 7 (1998) 1124-1127
9. Monnet I., Soulie P., de Cremoux H., Saltiel-Voisin S., Bekradda M., Saltiel J.C., et al. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 19 2 (2001) 458-463
10. Winegarden J.D., Mauer A.M., Otterson G.A., Rudin C.M., Villalona-Calero M.A., Lanzotti V.J., et al. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 15 6 (2004) 915-920
11. Bidoli P., Cortinovis D., Isa L., Fusi A., Pari F., Cullurà D., et al. Preliminary results of a randomized phase II three-arm, multicentric study of carboplatin + gemcitabine (CBDCA + GEM), or oxaliplatin (L-OHP) + GEM, or sequential CBDCA + GEM → docetaxel (DCT) + GEM in chemo-naive patients (pts) with advanced/metastatic non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol (2005) 648s [abstr 7118]
12. Broad A., Links M., Rosenthal M.A., and Mitchell P. Combination gemcitabine and oxaliplatin for advanced non-small-cell lung cancer (NSCLC): an Australian multicenter randomized phase II sequencing trial. Proc Am Soc Clin Oncol (2005) 681s [abstr 7244]
13. Cappuzzo F., Novello S., De Marinis F., Franciosi V., Maur M., Ceribelli A., et al. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer 93 1 (2005) 29-34
14. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21 16 (2003) 3016-3024
15. Kubota K., Watanabe K., Kunitoh H., Noda K., Ichinose Y., Katakami N., et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22 2 (2004) 254-261
16. Lorigan P., Booton R., Ashcroft L., O'Byrne K., Anderson H., Nicolson M., et al. Randomized phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small-cell lung cancer (NSCLC)-final results of a British Thoracic Oncology Group (BTOG) trial. Proc Am Soc Clin Oncol (2004) 632s [abstr 2004]
17. Antonini-Cappellini G.C., Flati V., Laglia E., Ronzino G., Porzio G., Ricevuto E., et al. Oxaliplatin (l-OHP) association with paclitaxel (PTX) or docetaxel (DTX) in NSCLC cell lines: schedule-dependent activity based on p53/microtubule associated protein 4 (MAP4) interaction. Ann Oncol 13 Suppl. 5 (2002) 17-18 [abstr 61P]
18. Kouroussis C., Agelaki S., Mavroudis D., Kakolyris S., Androulakis N., Kalbakis K., et al. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small-cell lung cancer. Anticancer Res 23 1B (2003) 785-791
19. ® (docetaxel) injection concentrate prescribing information. Bridgewater, NJ: Aventis Pharmaceuticals Inc.; 2005.
20. Eloxatin™ (oxaliplatin injection) prescribing information. New York, NY: Sanofi-Synthelabo Inc.; 2005.
21. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
22. Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute (Accessed November 8, 2005 at http://www.ctep.info.nih.gov/reporting/ctcnew.html).
23. Armitage P., Berry G., and Mathews J.N.S. Statistical methods in medical research. 4th ed. (2002), Blackwell Scientific, Oxford, UK
24. Parmar M.K.B., and Machin D. Survival analysis: a practical approach (1995), John Wiley and Sons, Cambridge, UK
25. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 25 (2005) 5892-5899
26. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 13 (2001) 3210-3218
27. Kosmidis P., Mylonakis N., Nicolaides C., Kalophonos C., Samantas E., Boukovinas J., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20 17 (2002) 3578-3585
28. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 346 2 (2002) 92-98
29. Franciosi V., Barbieri R., Aitini E., Vasini G., Cacciani G.C., Capra R., et al. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small-cell lung cancer patients. Lung Cancer 41 1 (2003) 101-106
30. Lippe P., Mazzanti P., Recchia F., Massacesi C., Cappelletti C., Imperatori L., et al. Gemcitabine-oxaliplatin combination (GEM-OHP) in metastatic non-small-cell lung cancer (NSCLC): final results of a phase II study. Proc Am Soc Clin Oncol (2005) 693s [abstr 7293]
31. De Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
32. Scagliotti G., Kortsik C., Dark G., Price A., Manegold C., Rosell R., et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small-cell lung cancer: a multicenter, randomized, Phase II trial. Clin Cancer Res 11 (2005) 690-696